Memantine
- PDF / 157,172 Bytes
- 14 Pages / 504.567 x 720 pts Page_size
- 104 Downloads / 185 Views
Pharmacoeconomics 2005; 23 (2): 193-206 1170-7690/05/0002-0193/$34.95/0 © 2005 Adis Data Information BV. All rights reserved.
Memantine A Pharmacoeconomic Review of its Use in Moderate-to-Severe Alzheimer’s Disease Greg L. Plosker and Katherine A. Lyseng-Williamson Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: N. Bosanquet, Department of Primary Health Care & General Practice, School of Medicine, Imperial College, London, England; S. Gauthier, McGill Center for Studies in Aging, Montreal, Qu´ebec, Canada; D.S. Knopman, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA; L. Parnetti, Department of Neuroscience, University of Perugia, Perugia, Italy; F.A. Schmitt, Department of Neurology, University of Kentucky Medical Center, Alzheimer’s Disease Research Center, Lexington, Kentucky, USA; A. Wimo, The Research Unit of Primary Health Care in Noranstig, Bergsjo, Sweden; B. Winblad, Department of Clinical Neuroscience & Family Medicine, Huddinge University Hospital, Huddinge, Sweden.
Data Selection Sources: Medical literature published in any language since 1980 on memantine, identified using Medline and Embase, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: Medline search terms were ‘memantine’ or ‘Alzheimers disease’ and (‘economics’ or ‘health-policy’ or ‘quality-of-life’ or ‘models-statistical’ or ‘health-planning’ or ‘epidemiology’ or ‘guideline in pt’ or ‘practice-guidelines in pt’. Embase search terms were ‘memantine’ or ‘Alzheimers disease’ and (‘economics’ or ‘health economics’ or ‘economic evaluation’ or ‘health status’ or ‘pharmacoeconomics’ or ‘drug cost’ or ‘drug utilization’ or ‘utilization review’ or ‘health survey’ or ‘practice guideline’ or ‘quality of life’ or ‘treatment outcome’ or ‘cost’ or ‘cost benefit analysis’ or ‘cost control’ or ‘cost effectiveness analysis’ or ‘cost minimisation analysis’ or ‘cost of illness’ or ‘cost utility analysis’). AdisBase search terms were ‘memantine’ or ‘Alzheimers disease’ and (‘health-economics’ or ‘pharmacoepidemiology’ or ‘prescribing’ or ‘hospitalisation’ or ‘formularies’ or ‘drug-utilisation’ or ‘meta-analysis’ or ‘therapeutic-substitution’ or ‘epidemiology’), or ‘memantine’ and ‘Alzheimers disease’. Searches were last updated 25 January 2005. Selection: Economic analyses in patients with moderate-to-severe Alzheimer’s disease who received memantine. Inclusion of studies was based mainly on the methods section of the trials. Relevant background data on epidemiology and cost of illness are also included. Index terms: Memantine, NMDA antagonists, Alzheimer’s disease, pharmacoeconomics, cost effectiveness, therapeutic use.
Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Data Loading...
